{"title":"Causal relationship between Alzheimer's disease and cerebral small vessel disease: a Mendelian randomization study.","authors":"Renjie Liu, Lanlan Chen, Xuan Chen","doi":"10.1038/s41398-025-03560-8","DOIUrl":null,"url":null,"abstract":"<p><p>Observational studies have produced inconsistent findings regarding the relationship between Alzheimer's disease (AD) and cerebral small vessel disease (CSVD) risk. Residual confounding and potential reverse causality are inevitable in such conventional observational studies. We tried to examine the causal relationship between AD and CSVD-related phenotypes using genetic methods. Genetic instruments for each AD and CSVD-related phenotypes (cerebral microbleeds, white matter hyperintensity, and lacunar stroke) were derived from large-scale genome-wide association studies. In this study, two-sample Mendelian randomization (MR) tested potential causal associations between AD and CSVD-related phenotypes, followed by a colocalization analysis to corroborate MR findings and explain possible mechanisms. Using univariable MR, we observed that genetic liability to AD was associated with an increased risk of cerebral microbleeds (CMBs) [odds ratio (OR) = 1.149; 95% confidence interval (CI) = 1.070-1.235, P < 0.001], and a modest increase in white matter hyperintensities (WMHs) volume (β = 0.031 mm<sup>3</sup>, 95% CI = 0.009-0.054 mm<sup>3</sup>, P = 0.005). In multivariable MR, the causal effect of genetic liability for AD on CMBs and WMHs remained after adjusting for risk factors, with the estimate across the IVW method. Colocalization results provided evidence for a shared causal variant between AD with CMBs (PPH4 = 0.996) and WMHs (PPH4 = 0.657), suggesting that the MR estimates were not confounded by linkage disequilibrium. Our MR analyses provided robust evidence for the causal effects of genetic liability for AD on an increased risk of CMBs and WMHs. More work is warranted to confirm the mechanisms of association between AD and CSVD.</p>","PeriodicalId":23278,"journal":{"name":"Translational Psychiatry","volume":"15 1","pages":"317"},"PeriodicalIF":6.2000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12381051/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41398-025-03560-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Observational studies have produced inconsistent findings regarding the relationship between Alzheimer's disease (AD) and cerebral small vessel disease (CSVD) risk. Residual confounding and potential reverse causality are inevitable in such conventional observational studies. We tried to examine the causal relationship between AD and CSVD-related phenotypes using genetic methods. Genetic instruments for each AD and CSVD-related phenotypes (cerebral microbleeds, white matter hyperintensity, and lacunar stroke) were derived from large-scale genome-wide association studies. In this study, two-sample Mendelian randomization (MR) tested potential causal associations between AD and CSVD-related phenotypes, followed by a colocalization analysis to corroborate MR findings and explain possible mechanisms. Using univariable MR, we observed that genetic liability to AD was associated with an increased risk of cerebral microbleeds (CMBs) [odds ratio (OR) = 1.149; 95% confidence interval (CI) = 1.070-1.235, P < 0.001], and a modest increase in white matter hyperintensities (WMHs) volume (β = 0.031 mm3, 95% CI = 0.009-0.054 mm3, P = 0.005). In multivariable MR, the causal effect of genetic liability for AD on CMBs and WMHs remained after adjusting for risk factors, with the estimate across the IVW method. Colocalization results provided evidence for a shared causal variant between AD with CMBs (PPH4 = 0.996) and WMHs (PPH4 = 0.657), suggesting that the MR estimates were not confounded by linkage disequilibrium. Our MR analyses provided robust evidence for the causal effects of genetic liability for AD on an increased risk of CMBs and WMHs. More work is warranted to confirm the mechanisms of association between AD and CSVD.
期刊介绍:
Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod''s discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.